Navigation Links
Aratana Therapeutics Adds To Drug Development Team
Date:3/26/2013

KANSAS CITY, Kan. and BOSTON, March 26, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing innovative prescription medications for cats and dogs (companion animals), today announced it has expanded its relationship with Marie-Paul Lachaud , DVM, as a consultant to the company who will lead drug evaluation and development in Europe.  Dr. Lachaud is a seasoned animal health executive whose work has led to significant companion animal health product approvals in Europe.  Additionally, Aratana expanded its U.S. drug development team to include Laura Simon Treml , VMD, Ph.D., as Director of Drug Development and Glenda L. Armintrout as Senior Research Associate, each of whom bring significant expertise in overseeing clinical programs in companion animals. 

Ernst Heinen , DVM, Ph.D., Head of Aratana's Drug Evaluation and Development, stated, "We're delighted that Marie-Paul has expanded her role with us.  Her engagement represents Aratana's first presence outside of the United States, and we could not ask for a better suited professional to lead our development efforts for the European market.  We are also fortunate to add Laura and Glenda to our team, as we focus on execution of our clinical development programs for our current drug candidates.  Given the strength of their backgrounds in companion animal drug development, we believe we will be well served by their expertise."

Marie-Paul Lachaud , DVM
Dr. Lachaud, whose prior experience focused on international development for animal drugs, was the European animal health director at ICON Clinical Research in Paris, France from 2000 to 2008.  In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on clinical drug development and regulatory affairs, which was acquired by ICON in 2000.

Primarily focused on transitioning human drugs to meet the needs of veterinary medicine, Dr. Lachaud's work has resulted in significant companion animal health product approvals in Europe and the U.S. in a number of innovative therapeutic areas, including reproduction, atopic dermatitis, chronic heart failure, wound healing, chronic kidney disease, pain, obesity, oncology, cognitive dysfunction and anxiety-related disorders.

As Head of Business and Product Development Europe, her responsibilities include coordinating the European Regulatory process for Aratana's products and running the company's in-licensing and out-licensing activities in Europe.

She received her veterinary degree from Alfort National Veterinary School in Paris and her doctorate in veterinary medicine from the University of Paris, France.

Laura Simon Treml , VMD, Ph.D.
Prior to her appointment at Aratana, Dr. Treml led clinical development programs for dogs and cats and managed the Companion Animal Efficacy group at Bayer Animal Health.  Earlier in her career, she practiced small animal medicine and surgery on the East Coast for nine years.

As Director of Drug Development at Aratana, Dr. Treml's responsibilities include designing and managing several of the company's drug development programs and scientifically evaluating potential new in-licensing drug candidates.

Dr. Treml received both her veterinary degree and her Ph.D. in Immunology from the University of Pennsylvania. 

Glenda L. Armintrout
Prior to joining Aratana, Ms. Armintrout was a project manager and scientist at Xenometrics, a contract laboratory specializing in a number of services in support of drug development.  At Xenometrics, she was responsible for monitoring and managing companion animal preclinical studies.  Ms. Armintrout has also held project management and scientist positions at Aptuit and Bayer, and has worked as a Registered Veterinary Technician (RVT) in a companion animal practice.

As a Senior Research Associate at Aratana, Ms. Armintrout is responsible for assisting the oversight of laboratory and clinical animal studies, organizing data, technical writing and interacting with contract research organizations.

Ms. Armintrout has a BS from Friends University in Kansas City, KS, and an AA in animal health technology from Murray State College in Tishomingo, OK. 

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company focused on addressing unmet and underserved medical needs in pets.  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and develops strategies to maximize the value of the programs for the pet market.  For more information, please visit www.aratana.com.

Contacts:
Tiberend Strategic Advisors, Inc. 
Joshua Drumm , Ph.D./ Andrew Mielach
jdrumm@tiberend.com; (212) 375-2664
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
4. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
8. Fate Therapeutics Strengthens Its iPSC Platform
9. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
10. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
11. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology:
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
Breaking Biology News(10 mins):